Epacadostat
Clinical data | |
---|---|
ATC code | |
Identifiers | |
| |
JSmol) | |
| |
|
Epacadostat (previously INCB24360) is an
indoleamine 2,3-dioxygenase-1 (IDO1).[1][2][3] Epacadostat inhibits IDO1 by competitively blocking it, without interfering with IDO2 or tryptophan 2,3-dioxygenase (TDO). It has antitumor activity in some models, though is most effective when combined with other immunotherapy agents.[4]
History and clinical trials
As of 2017, the combination of epacadostat with pembrolizumab (Keytruda) was being investigated by Incyte and Merck & Co. in several cancers, as was the combination of epacadostat with nivolumab (Opdivo) by Incyte and Bristol Myers Squibb.[5]
In April 2018, Incyte announced they were halting the Phase III ECHO-301/KEYNOTE-252 (NCT02752074) trial of epacadostat with pembrolizumab for melanoma as the combination therapy missed the first
overall survival is not yet determined.[6]
References
- ^ a b "Epacadostat". NCI Drug Dictionary. National Cancer Institute. 2011-02-02.
- PMID 28324751.
- PMID 28523098.
- .
- ^ Staton T (3 April 2017). "Racing in lung cancer again (or still), Merck and BMS expand Incyte combo trials". FiercePharma.
- ^ a b "Incyte, Merck & Co. Halt Phase III Trial After Epacadostat/Keytruda Combination Fails in Melanoma". 6 April 2018.
- ^ Walters J (6 April 2018). "Incyte Tumbles After Epacadostat Miss". BioCentury.